| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, 4000 Liège, Belgium
Address all correspondence and requests for reprints to: Professor Albert Beckers, M.D., Ph.D., Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium. E-mail: albert.beckers{at}chu.ulg.ac.be.
Context: Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce.
Objective: The objective of the study was to measure the prevalence of clinically relevant pituitary adenomas in a well-defined population.
Design: This was a cross-sectional, intensive, case-finding study performed in three regions of the province of Liège, Belgium, to measure pituitary adenoma prevalence as of September 30, 2005.
Setting: The study was conducted in specialist and general medical practitioner patient populations, referral hospitals, and investigational centers.
Methods: Three demographically and geographically distinct districts of the province of Liège were delineated precisely using postal codes. Medical practitioners in these districts were recruited, and patients with pituitary adenomas under their care were identified. Diagnoses were confirmed after retrieval of clinical, hormonal, radiological, and pathological data; full demographic and therapeutic follow-up data were collected in all cases.
Results: Sixty-eight patients with clinically relevant pituitary adenomas were identified in a population of 71,972 individuals; the mean (± SD) prevalence was 94 ± 19.3 cases per 100,000 population (95% confidence interval, 72.2 to 115.8). The group was 67.6% female and had a mean age at diagnosis of 40.3 yr; 42.6% had macroadenomas and 55.9% underwent surgery. Prolactinomas comprised 66% of the group, with the rest having nonsecreting tumors (14.7%), somatotropinomas (13.2%), or Cushing’s disease (5.9%); 20.6% had hypopituitarism.
Conclusion: The prevalence of pituitary adenomas in the study population (one case in 1064 individuals) was more than 3.5–5 times that previously reported. This increased prevalence may have important implications when prioritizing funding for research and treatment of pituitary adenomas.
This article has been cited by other articles:
 |
|
 |
|
  J. E Jennings, M. Georgitsi, I. Holdaway, A. F Daly, M. Tichomirowa, A. Beckers, L. A Aaltonen, A. Karhu, and F. J Cameron Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene Eur. J. Endocrinol., November 1, 2009; 161(5): 799 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gutenberg, J. Larsen, I. Lupi, V. Rohde, and P. Caturegli A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary Adenoma Preoperatively AJNR Am. J. Neuroradiol., October 1, 2009; 30(9): 1766 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S K Khoo, R Pendek, R Nickolov, D C Luccio-Camelo, T L Newton, A Massie, D Petillo, J Menon, D Cameron, B T Teh, et al. Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma Endocr. Relat. Cancer, September 1, 2009; 16(3): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mukherjee, H. A Zaidi, T. Kosztowski, K. L Chaichana, R. Salvatori, D. C Chang, and A. Quinones-Hinojosa Predictors of access to pituitary tumor resection in the United States, 1988-2005 Eur. J. Endocrinol., August 1, 2009; 161(2): 259 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kars, P. C. Souverein, R. M. C. Herings, J. A. Romijn, J. P. Vandenbroucke, A. de Boer, and O. M. Dekkers Estimated Age- and Sex-Specific Incidence and Prevalence of Dopamine Agonist-Treated Hyperprolactinemia J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2729 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Schoemaker and A. J. Swerdlow Risk Factors for Pituitary Tumors: A Case-control Study Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1492 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Elston, A. J. Gill, J. V. Conaglen, A. Clarkson, R. J. Cook, N. S. Little, B. G. Robinson, R. J. Clifton-Bligh, and K. L. McDonald Nuclear Accumulation of E-Cadherin Correlates with Loss of Cytoplasmic Membrane Staining and Invasion in Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1436 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Acunzo, S. Thirion, C. Roche, A. Saveanu, G. Gunz, A. L. Germanetti, B. Couderc, R. Cohen, D. Figarella-Branger, H. Dufour, et al. Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas Cancer Res., December 15, 2008; 68(24): 10163 - 10170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Pesatori, A. Baccarelli, D. Consonni, A. Lania, P. Beck-Peccoz, P. A. Bertazzi, and A. Spada Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident Eur. J. Endocrinol., December 1, 2008; 159(6): 699 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lancellotti, E. Livadariu, M. Markov, A. F Daly, M.-C. Burlacu, D. Betea, L. Pierard, and A. Beckers Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol., July 1, 2008; 159(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vazquez-Martinez, A. J. Martinez-Fuentes, M. R. Pulido, L. Jimenez-Reina, A. Quintero, A. Leal-Cerro, A. Soto, S. M. Webb, N. Sucunza, F. Bartumeus, et al. Rab18 Is Reduced in Pituitary Tumors Causing Acromegaly and Its Overexpression Reverts Growth Hormone Hypersecretion J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2269 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Honegger, S. Zimmermann, T. Psaras, M. Petrick, M. Mittelbronn, U. Ernemann, M. Reincke, and K. Dietz Growth modelling of non-functioning pituitary adenomas in patients referred for surgery Eur. J. Endocrinol., March 1, 2008; 158(3): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Beckers and A. F Daly The clinical, pathological, and genetic features of familial isolated pituitary adenomas Eur. J. Endocrinol., October 1, 2007; 157(4): 371 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A Naves, A. F Daly, J.-F. Vanbellinghen, L. A Casulari, C. Spilioti, A. V Magalhaes, M. F Azevedo, L. A Giacomini, P. P Nascimento, R. O Nunes, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene Eur. J. Endocrinol., October 1, 2007; 157(4): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Kars, A A van der Klaauw, C S Onstein, A M Pereira, and J A Romijn Quality of life is decreased in female patients treated for microprolactinoma Eur. J. Endocrinol., August 1, 2007; 157(2): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Caturegli Autoimmune Hypophysitis: An Underestimated Disease in Search of Its Autoantigen(s) J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2038 - 2040. [Full Text] [PDF]
|
|
|
|
|
|
A. F. Daly, J.-F. Vanbellinghen, S. K. Khoo, M.-L. Jaffrain-Rea, L. A. Naves, M. A. Guitelman, A. Murat, P. Emy, A.-P. Gimenez-Roqueplo, G. Tamburrano, et al. Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1891 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hemminki, A. Forsti, and J. Ji Incidence and familial risks in pituitary adenoma and associated tumors Endocr. Relat. Cancer, March 1, 2007; 14(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
